Aurinia Pharmaceuticals Inc.: management transactions · United States · SEC (Form 4)

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. (ticker: AUPH) is a US-listed biopharmaceutical company traded on the NASDAQ in the United States. From an international equity perspective, Aurinia is best understood as a focused specialty pharma business rather than a broad-based drug developer: its core thesis centers on autoimmune and kidney diseases with significant unmet medical need. The company has Canadian historical roots, but its current commercial identity is anchored in the US market and in the lifecycle management of its lead asset, voclosporin. Aurinia’s key commercial product is LUPKYNIS® (voclosporin), which the company describes as the first FDA-approved oral therapy for adult patients with active lupus nephritis. That approval marked a decisive transition from a development-stage biotech to a commercial-stage biopharmaceutical company with product revenue. The company’s business model is therefore highly concentrated: it focuses on developing, commercializing, and expanding access to therapies for targeted patient populations, particularly in autoimmune and renal disease settings. Competitively, Aurinia operates in a specialized and clinically demanding market. Lupus nephritis is a serious and difficult-to-treat condition, which means market share depends not only on efficacy and safety, but also on physician adoption, reimbursement access, and the company’s ability to execute commercially. Aurinia’s differentiation lies in its oral therapy profile, regulatory positioning, and the fact that it controls a branded product in a niche indication where treatment options remain limited. This concentration can be a strength if adoption continues, but it also creates product-specific risk. Geographically, Aurinia is primarily centered on North American operations, with the United States as the main commercial and regulatory platform. The company has also sought to broaden the reach of voclosporin beyond the US through international regulatory and partnership pathways, reflecting a broader aspiration to build value across multiple markets. Historically, the business traces back to Isotechnika Pharma Inc., founded in 1993, which gives Aurinia a long development history before the eventual launch of LUPKYNIS. Recent company disclosures show continued commercial momentum for LUPKYNIS, with year-over-year revenue growth in the latest reported periods. For investors, that is an important signal: Aurinia’s story is increasingly about execution, market penetration, and sustaining the commercial value of an approved therapy rather than binary clinical-stage outcomes. In short, Aurinia is a NASDAQ-listed United States biopharma company with a concentrated but strategically important niche in lupus nephritis and autoimmune disease treatment.